FibroBiologics (FBLG) Liabilities and Shareholders Equity (2022 - 2026)

FibroBiologics has reported Liabilities and Shareholders Equity for 5 years, with the latest figure at $7.9 million in Q2 2026.

• Liabilities and Shareholders Equity for Q2 2026 came in at $7.9 million, down 42.99% year-over-year; the trailing twelve-month figure through Jun 2026 was $32.2 million (down 38.31% YoY), and the FY2025 annual result was $9.6 million, down 41.51% from the prior year.
• Liabilities and Shareholders Equity grew to $7.9 million in Q2 2026, from $5.9 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $16.4 million in Q4 2024 and troughed at $4.8 million in Q4 2022.
• A 5-year average of $10.1 million and a median of $10.0 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The widest annual swing landed in 2023, when Liabilities and Shareholders Equity soared 145.05%; it then slumped 48.03% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $4.8 million in 2022, then soared by 145.05% to $11.8 million in 2023, then surged by 39.12% to $16.4 million in 2024, then tumbled by 41.51% to $9.6 million in 2025, then decreased by 17.57% to $7.9 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $7.9 million in Q2 2026, $5.9 million in Q1 2026, and $9.6 million in Q4 2025.